{"entity":{"id":"paper-nct05199272-cancer-res-commun-2025","kind":"paper","name":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies","aka":[],"tldr":"Published report from the trial registered as NCT05199272, in Cancer research communications (2025), chosen as the most cited paper whose own text cites the registry id.","summary":"Purpose: In this phase 1 portion of a first-in-human phase 1/2a study (NCT05199272), 23ME-00610 was evaluated in participants with advanced solid malignancies to determine its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). Exploratory biomarkers were evaluated to examine potential correlates of efficacy and safety.\n\nPatients and methods: Eligible participants (≥18 years) were administered 23ME-00610 intravenously every 3 weeks (Q3W) using an accelerated titration design followed by a traditional 3 + 3 design, with an initial dose level of 2 mg.\n\nResults: Twenty-eight participants were enrolled across seven cohorts and received a median of four cycles of 23ME-00610. No treatment-related serious adverse events (AE) were observed, and the maximum tolerated dose was not reached. Overall, the PK of 23ME-00610 was linear and dose proportional for doses ≥60 mg, with a median terminal half-life of 13 days at 1,400 mg. Peripheral saturation of CD200R1 was observed for doses ≥60 mg. Immune-related AEs, including rash, pruritus, and hypothyroidism, were predicted by phenome-wide association studies and observed for doses ≥60 mg. A confirmed partial response was observed in a participant with well-differentiated pancreatic neuroendocrine cancer whose tumor was among those with the highest tumor CD200 expression.\n\nConclusions: 23ME-00610 has mild-to-moderate on-target AEs and PK/PD consistent with tumor target saturation and dosing every 3 weeks. The trend for clinical benefit in participants with tumor CD200 expression suggests that 23ME-00610 inhibits CD200R1 signaling and may reverse CD200-mediated immune evasion. Based on PK/PD, safety, and preliminary antitumor activity, 1,400 mg Q3W was selected as the dose for further study.\n\nSignificance: Genome-wide association studies (GWAS) of the 23andMe genetic database identified CD200R1 as a promising therapeutic target for cancer. This phase 1 study of 23ME-00610, a CD200R1 antagonist IgG1, showed acceptable safety and tolerability, PK supporting Q3W dosing, and PD and preliminary clinical activity supporting an initial recommended phase 2 dose of 1,400 mg.\n\nIndexed on Europe PMC as PubMed record 39651931 (DOI 10.1158/2767-9764.crc-24-0568). Its abstract cites the registry id NCT05199272, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Cancer Res Commun 2025","url":"https://doi.org/10.1158/2767-9764.crc-24-0568"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/39651931/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/39651931"},{"label":"ClinicalTrials.gov NCT05199272","url":"https://clinicaltrials.gov/study/NCT05199272"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05199272"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-research-communications"],"dependsOn":[],"notes":[],"journal":"Cancer research communications","year":2025,"doi":"10.1158/2767-9764.crc-24-0568","pmid":"39651931","authors":"Kummar S, Razak AA, Laurie S, et al.","paperType":"observational","findings":[],"whatItMeans":"This is the paper Europe PMC returns for registry id NCT05199272 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-nct05199272-cancer-res-commun-2025/","neighbours":{"trial":[{"id":"nct05199272","kind":"trial","name":"A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies","route":"/trials/nct05199272/"}],"journal":[{"id":"cancer-research-communications","kind":"journal","name":"Cancer research communications","route":"/journals/cancer-research-communications/"}]}}